In a registry-based analysis, more hospitalized children with SCD and COVID-19 had severe infection requiring supplemental oxygen, compared with the general population.
This article was originally published by HCPLive.
A new analysis of data from the Pediatric COVID-19 United States Registry revealed children with sickle cell disease (SCD) are at risk of severe disease with SARS-CoV-2 infection.1
According to the registry-based analysis, approximately one-third of children with SCD required hospitalization with nearly half of the children with SCD who were hospitalized requiring supplemental oxygen.
Model of Sickled Cells | image credit: Sebastian Kaulitzki - stock.adobe.com
“Our results indicate that a higher proportion of hospitalized children with SCD and COVID-19 had severe infection requiring supplemental oxygen compared to the general population, a finding that has been showing in other viral illnesses, particularly influenza,” wrote the investigative team led by Aleksandra S. Dain, MD, division of hematology, department of pediatrics at the Children’s Hospital of Philadelphia.
Adults with SCD are known to be at increased risk of SARS-CoV-2-related complications, including hospitalization, compared with a healthy population.2 Its exact mechanism remains unknown, but research has cited pre-existing end-organ damage as a potential cause. Hospitalization and mortality in SCD are often comparable to non-SCD populations with similar comorbidities.
Among children, those with underlying comorbidities and those who develop multisystem inflammatory syndrome (MIS-C) experience elevated morbidity and mortality secondary to SARS-CoV-2 infection.3 Reports suggest SCD is a risk for severe COVID-19 and hospitalization, but limitations of these findings include single-center populations or a lack of non-SCD comparators.
In this registry-based analysis, Dain and colleagues sought to describe the clinical characteristics and outcomes of both acute COVID-19 and MIS-C in pediatric patients with SCD and compare these findings with other populations.1
The Pediatric COVID-19 US Registry involved surveillance of pediatric COVID-19 cases diagnosed between March 2020 and April 2021. Eligible cases were individuals ≤ 21 years of age diagnosed with laboratory-confirmed SARS-CoV-2 infection. Hospitalizations, including intensive care unit (ICU) admissions, were documented.
Overall, the registry included 13,140 patients, and the primary analysis used 10,974 children with complete study data. Investigators identified a total of 263 patients with SCD. The study population had a median age of 12 years, and 140 (53%) patients were male.
Among those with SCD, 91 (35%) patients were hospitalized due to COVID-19, compared with 114 (34%) in the immune-compromised group and 1485 (14%) in the general pediatric populations. Notably, significantly fewer hospitalized patients with SCD required ICU care (18%) compared with the immune-compromised (32%; P = .016) and general pediatric groups (35%; P = .001).
In children who were hospitalized, those in the SCD cohort demonstrated the highest proportion of patients requiring supplemental oxygen (45%) compared with the immune-compromised (37%) and general pediatric (35%) cohorts. However, the between-group differences were not statistically significant (P = .17).
A total of 4 hospitalized (4.4%) patients with SCD in the cohort were diagnosed with MIS-C, compared with 2 (1.75%) and 288 (19.4%) in the hospitalized immune-compromised and general pediatric groups, respectively. All those with SCD or immune-compromised required ICU admission, compared with two-thirds of general pediatric patients.
Despite the COVID-19 global public health emergency ending, Dain and colleagues indicated that SARS-CoV-2 infection remains a persistent and relevant respiratory pathogen, particularly for those with SCD.
“The opportunity remains to protect vulnerable patients, including those with SCD, through optimization of vaccination and supportive care,” they wrote.
References
Areas of Unmet Need Continue to Burden Patients With gMG
April 2nd 2025Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those treating and being treated for the chronic autoimmune neuromuscular disorder, to have a more nuanced understanding of experiences and difficulties.
Read More
Financial, Housing, Food Insecurity Raise Risk of Hospital, ED Visits
April 1st 2025Social determinants of health been long understood to influence health outcomes, and this new analysis explores more deeply the link between social risk exposure and rates of health care resource utilization.
Read More
Managed Care Reflections: A Q&A With Hoangmai H. Pham, MD, MPH
April 1st 2025To mark the 30th anniversary of The American Journal of Managed Care® (AJMC®), each issue in 2025 will include a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The April issue features a conversation with Hoangmai H. Pham, MD, MPH, a member of AJMC’s editorial board and the president and CEO of the Institute for Exceptional Care (IEC).
Read More